Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc.

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025.

On July 24, 2025, Pfizer Inc. (NYSE:PFE) finalized the global licensing agreement with 3SBio, Inc. With this agreement, PFE acquired the exclusive rights to develop, manufacture, and commercialize 3SBio’s SSGJ-707, a bispecific antibody for PD-1 and VEGF. Leveraging 3SBio’s proprietary CLF2 platform, this innovative treatment enhances Pfizer’s oncology pipeline and solidifies its competitive edge in cancer research.

The antibody is presently undergoing clinical trials in China for non-small cell lung cancer (NSCLC) with promising interim Phase 2 results. It is also under clinical trials for gynecological tumors. By manufacturing the drug in the U.S. and expanding clinical trials globally, Pfizer Inc. (NYSE:PFE) aims to focus on Phase 3 studies for NSCLC and other solid tumors.

Pfizer Inc. (NYSE:PFE) will make an upfront payment of $1.25 billion to 3SBio and acquire a $100 million equity stake, as per the agreed terms. With up to $150 million in potential payments, Pfizer Inc. (NYSE:PFE) can exercise the option to extend the agreement for exclusive rights in China.

Operating globally, Pfizer Inc. (NYSE:PFE) discovers, develops, and sells biopharmaceuticals. It is one of the best ESG stocks.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.